STAAR Surgical Company (STAA)
| Market Cap | 1.32B +49.8% |
| Revenue (ttm) | 239.44M -23.7% |
| Net Income | -80.45M |
| EPS | -1.62 |
| Shares Out | 49.51M |
| PE Ratio | n/a |
| Forward PE | 48.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 445,960 |
| Open | 27.48 |
| Previous Close | 27.28 |
| Day's Range | 26.38 - 27.48 |
| 52-Week Range | 15.59 - 30.81 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 22.81 (-14.54%) |
| Earnings Date | May 13, 2026 |
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers... [Read more]
Financial Performance
In fiscal year 2025, STAAR Surgical Company's revenue was $239.44 million, a decrease of -23.72% compared to the previous year's $313.90 million. Losses were -$80.45 million, 298.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for STAA stock is "Buy." The 12-month stock price target is $22.81, which is a decrease of -14.54% from the latest price.
News
STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Staar Surgical price target raised to $26 from $21 at Wedbush
Wedbush raised the firm’s price target on Staar Surgical (STAA) to $26 from $21 and keeps a Neutral rating on the shares. The firm notes Staar announced that it expects
Staar Surgical upgraded to Buy from Hold at Canaccord
Canaccord upgraded Staar Surgical (STAA) to Buy from Hold with a price target of $27, up from $22. The company announced preliminary Q1 revenue of over $90M, well above estimates,
Staar Surgical up 18% at $24.64 after above-consensus Q1 pre-announcement
16:04 EDT Staar Surgical (STAA) up 18% at $24.64 after above-consensus Q1 pre-announcement
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Staar Surgical price target lowered to $22 from $28 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on Staar Surgical (STAA) to $22 from $28 and keeps a Neutral rating on the shares. The firm says the company
Staar Surgical price target lowered to $18 from $19 at Stifel
Stifel lowered the firm’s price target on Staar Surgical (STAA) to $18 from $19 and keeps a Hold rating on the shares. Q4 results were “somewhat noisy,” says the analyst.
STAAR Surgical Company Earnings Call Transcript: Q4 2025
2025 marked a transition year with cost reductions, leadership changes, and inventory normalization, setting the stage for targeted growth and profitability in 2026. Q4 net sales rose 18% year-over-year, with strong cash reserves and optimism for China and global recovery.
STAAR Surgical Issues Shareholder Letter
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
FDA approved expanded age indication for EVO/EVO+ Visian implantable lenses
The company states: “STAAR Surgical (STAA) Company announced that the U.S. Food and Drug Administration has approved an expanded age indication for EVO/EVO+ Visian(R) Implantable Collamer Lenses, exte...
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Staar Surgical price target lowered to $19 from $28 at Stifel
Stifel lowered the firm’s price target on Staar Surgical (STAA) to $19 from $28 and keeps a Hold rating on the shares. China refractive end market uncertainty seemingly persists, which
Staar Surgical initiated with a Neutral at Wedbush
Wedbush initiated coverage of Staar Surgical (STAA) with a Neutral rating and $26 price target While the firm believes Staar is a compelling valuation opportunity, trading at significant discounts to
Staar Surgical appoints COO Warren Foust, CFO Deborah Andrews as interim co-CEOs
Staar Surgical (STAA) announced that its board of directors has appointed Warren Foust, president and COO, and Deborah Andrews, CFO, as interim co-CEOs, effective February 1. Foust and Andrews will
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) ...
Staar Surgical resumed with an Underweight at Morgan Stanley
Morgan Stanley resumed coverage of Staar Surgical (STAA) with an Underweight rating and $13 price target after the company terminated its merger agreement with Alcon (ALC). While the EVO ICL
STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) ...
Alcon Terminates Agreement to Acquire STAAR Surgical
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing
STAAR Surgical said on Tuesday it plans to terminate its merger agreement with Swiss eyecare giant Alcon after failing to secure enough shareholder votes to approve the deal, sending its shares down m...
STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...